Clinical Trials Logo
  1. Home
  2. Hyperparathyroidism, Primary
  3. NCT00936988

A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Hyperparathyroidism, Primary Clinical Trial

Official title:
A Multicenter, Open-label Extension Study to Assess the Long-term Safety and Efficacy of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism

Clinical Trial Summary

This multicenter, open-label, single-arm, extension study was designed to evaluate long-term tolerability, safety, and efficacy of cinacalcet. Subjects were enrolled immediately after they completed the parent study, 990120. All subjects began treatment with 30 mg cinacalcet twice daily (BID), with dose adjustments made per protocol-specified guidelines. The study consisted of 2 consecutive phases that occurred in the following order: a dose-titration phase lasting 12 weeks and a maintenance phase lasting approximately 4½ years.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00936988
Study type Interventional
Source Amgen
Contact
Status Completed
Phase Phase 2
Start date November 2000
Completion date December 2005
View Details
See also
  Status Clinical Trial Phase
Completed NCT03764007 - 18F-Fluorocholine for the Detection of Parathyroid Adenomas Phase 2/Phase 3
Not yet recruiting NCT05556499 - The Bone-parathyroid Crosstalk in Primary Hyperparathyroidism
Completed NCT00928408 - PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice
Completed NCT00936650 - A Study to Assess the Efficacy and Safety of Twice-Daily Dose Regimens of an Oral Calcimimetic Agent AMG 073 (Cinacalcet) in Primary Hyperparathyroidism (PHPT) Phase 2
Recruiting NCT04948671 - Primary Hyperparathyroidism and Gut Microbiota
Completed NCT02417389 - Efficacy of Cinacalcet in the Control of Primary Hyperparathyroidism Phase 4
Completed NCT00975221 - Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy Phase 3
Recruiting NCT04895631 - 18F-Fluorocholine Positron Emission Tomography (PET) for the Detection of Parathyroid Adenomas Phase 3
Not yet recruiting NCT04126954 - Study on the Use of Cinacalcet in Phosphocalcic Context.
Recruiting NCT05152927 - Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Parathyroidectomy N/A
Recruiting NCT06230380 - Autofluorescence in Surgery for Primary Hyperparathyroidism N/A
Completed NCT03091140 - Alterations in Muscle's Functional Characteristics After Parathyroid Surgery for Primary Hyperparathyroidism.
Completed NCT03324893 - FCH PET/MRI Parathyroid Localization N/A
Completed NCT05347082 - Frequency of Hyperparathyroidism in Postmenopausal Osteoporosis and Its Treatment N/A